ArticleClinical and experimental immunology2015
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.
Article in Clinical and experimental immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Understanding the Immune System's Intricate Balance: Activation, Tolerance, and Self-Protection.International journal of molecular sciences · 2025Review
- Molecular Mechanisms and Therapeutic Implications of Human Pericyte-like Adipose-Derived Mesenchymal Stem Cells in an In Vitro Model of Diabetic Retinopathy.International journal of molecular sciences · 2024Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Metalloporphyrins Reduce Proteinuria in Podocyte Immune Injury: The Role of Metal and Porphyrin Moieties.International journal of molecular sciences · 2023Article
- Metalloporphyrins as Tools for Deciphering the Role of Heme Oxygenase in Renal Immune Injury.International journal of molecular sciences · 2023Review
- Salix subserrata Bark Extract-Loaded Chitosan Nanoparticles Attenuate Neurotoxicity Induced by Sodium Arsenate in Rats in Relation with HPLC-PDA-ESI-MS/MS Profile.AAPS PharmSciTech · 2022Article
- The Role of Heme Oxygenase-1 as an Immunomodulator in Kidney Disease.Antioxidants (Basel, Switzerland) · 2022Review
- The different facets of heme-oxygenase 1 in innate and adaptive immunity.Cell biochemistry and biophysics · 2022Review
- Contribution of Dysregulated DNA Methylation to Autoimmunity.International journal of molecular sciences · 2021Review
- Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4Antioxidants (Basel, Switzerland) · 2021Article
- Modulations of Cardiac Functions and Pathogenesis by Reactive Oxygen Species and Natural Antioxidants.Antioxidants (Basel, Switzerland) · 2021Review
- Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease.Frontiers in medicine · 2021Review
- Immune Modulation by Inhibitors of the HO System.International journal of molecular sciences · 2020Review
- Modulation of Inflammation and Immune Responses by Heme Oxygenase-1: Implications for Infection with Intracellular Pathogens.Antioxidants (Basel, Switzerland) · 2020Review
- The Cytoprotective Enzyme Heme Oxygenase-1 Suppresses Pseudorabies Virus ReplicationFrontiers in microbiology · 2020Article
- Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases.Frontiers in immunology · 2020Review
- Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.Immunology · 2019Article
- Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.Frontiers in immunology · 2019Review
- Heme Catabolic Pathway in Inflammation and Immune Disorders.Frontiers in pharmacology · 2019Review
- The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China.Arthritis research & therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus is characterized by the presence of circulating anti-nuclear antibodies (ANA) and systemic damage that includes nephritis, haematological manifestations and pulmonary compromise, among others. Although major progress has been made in elucidating the molecular mechanisms responsible for autoimmunity, current therapies for lupus have not improved considerably. Because the exposure of carbon monoxide (CO) has been shown to display beneficial immunoregulatory properties in different immune-mediated diseases, we investigated whether CO therapy improves lupus-related kidney injury in lupus mice. MRL-Fas(lpr) lupus mice were exposed to CO and disease progression was evaluated. ANA, leucocyte-infiltrating populations in spleen, kidney and lung and kidney lesions, were measured. CO therapy significantly decreased the frequency of activated B220(+) CD4(-) CD8(-) T cells in kidneys and lungs, as well as serum levels of ANA. Furthermore, we observed that CO therapy reduced kidney injury by decreasing proliferative glomerular damage and immune complexes deposition, decreased proinflammatory cytokine production and finally delayed the impairment of kidney function. CO exposure ameliorates kidney and lung leucocyte infiltration and delays kidney disease in MRL-Fas(lpr) lupus mice. Our data support the notion that CO could be explored as a potential new therapy for lupus nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.